Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma

Cancer

Volumn 77, Issue 11, 1996, Pages 2386-2392

  Stock, Richard G ^a,b   Stone, Nelson N ^a   Dewyngaert, J Keith ^a   Lavagnini, Pablo ^a   Unger, Pamela D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

biopsy; brachytherapy; isotope; potency; prostate carcinoma; prostate specific antigen

Indexed keywords

IODINE 125; PALLADIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BLADDER NECK STENOSIS; BRACHYTHERAPY; DOSE RESPONSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RADIATION DOSE; RADIOISOTOPE THERAPY; SEXUAL FUNCTION; TRANSURETHRAL RESECTION; URINE RETENTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BRACHYTHERAPY; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; IODINE RADIOISOTOPES; LIFE TABLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLADIUM; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOISOTOPES; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINATION DISORDERS;

EID: 0030008938     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960601)77:11<2386::AID-CNCR30>3.0.CO;2-R     Document Type: Article

References (45)

1. Hilaris BS, Whitmore WF, Batata M, Barzel W. Behavioral patterns of prostate adenocarcinoma following I-125 implant and pelvic node dissection. Int J Radiat Oncol Biol Phys 1977;2:631-7.
2. Deblasio DS, Hilaris BS, Nori D, Fuks Z, Whitmore WF, Fair WR, et al. Permanent interstitial implantation of prostatic cancer in the 1980s. Endocurie/Hypertherm Oncol 1988; 4:193-201.
3. Kuban DA, El-Mahdi AM, Schellhammer PF. I-125 interstitial implantation for prostate cancer: what have we learned 10 years later? Cancer 1989;63:2415-20.
4. Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Sem Radiat Oncol 1993;3:240-9.
5. Holm HH, Pederson JF, Hansen H, Stroyer I. Transperineal I-125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-6.
6. Wallner K, Chiu-Tsao S, Roy J, Artebery VE, Whitmore W, Jain S, et al. An improved method for computerized tomography-planned transperineal Iodine-125 prostate implants. J Urol 1991;146:90-5.
7. Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995;32:219-25.
8. Stone NN, Ramin SA, Wesson MF, Stock R, Unger P. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 1995;153:1555-60.
9. Beahrs OH, Henson DE, Hutter RV, Kennedy BJ. Prostate. In: Beahrs OH, Henson DE, Hutter RV, Kennedy BJ, Editors. Manual for staging of cancer. 4th ed. Philadelphia: JB Lippincott, 1992:181-3.
10. Stock RG, Stone NN, Ianuzzi C, Unger P. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:815-21.
11. Gleason DF and the Veterans Administration Cooperative Urologic Research Group. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, Editor. Urologic Pathology: the Prostate. Philadelphia: Lea & Febiger, 1977:171-87.
12. 125I seeds. Med Phys 1976;3:48-51.
13. Anderson LL, Moni JV, Harrison LB. A nomograph for permanent implants of palladium-103 seeds. Int J Radiat Oncol Biol Phys 1993;27:129-35.
14. Stone NN, Stock RG, DeWyngaert JK, Tabert A. Prostate brachytherapy: improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry. Radiat Oncol Invest 1995;3:185-95.
15. Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996. In press.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
17. Cox DR, Oakes D. Analysis of survival data. Chapman and Hall, 1984.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
19. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42.
20. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostate cancer: follow-up. J Urol 1993;149:519-22.
21. Pisansky TM, Cha SS, Earle JD, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
22. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786-91.
23. Zeitman AI, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
24. Zeitman AL, Edelstein RA, Coen JJ, et al. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-33.
25. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
26. Blasko JC, Wallner K, Grimm PD, Ragde H. PSA-based disease control following ultrasound-guided I-125 implantation for stage T1/T2 prostatic carcinoma. J Urol 1995; 154:1096-9.
27. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-83.
28. Kuban DA, El-Mahdi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys 1992;24:409-14.
29. Prestidge BR, Kaplan I, Cox RS, Bagshaw MA. Predictors of survival after a positive post-irradiation prostate biopsy. Int J Radiat Oncol Biol Phys 1993;28:17-22.
30. Crook J, Robertson S, Esche B. Proliferative cell nuclear antigen in postradiotherapy prostate biopsies. Int J Radiat Oncol Biol Phys 1994;30:303-8.
31. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsy following radiotherapy for prostate cancer: results for 226 patients. Urology 1994;45:624-32.
32. Delaney TF, Shipley WU, O'Leary PP, Biggs PJ, Prout GR. Int J Radiat Oncol Biol Phys 1986;12:1779-85.
33. Kim RY, Bueschen AJ, Saalter MM. Retropubic Iodine-125 seed implantation for prostate cancer. Endocurie/Hypertherm Oncol 1989;5:141-6.
34. Arterbery VE, Wallner K, Roy J, Fuks Z. Short-term morbidity from CT-planned transperineal I-125 prostate implants. Int J Radiat Oncol Biol Phys 1993;25:661-7.
35. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988;15:1307-16.
36. Helgason AR, Fredrikson M, Adolfsson J, Steineck G. Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life. Int J Radiat Oncol Biol Phys 1995;32:33-9.
37. Jonler M, Messing EM, Ritter MA, Rhodes PR, Brinkman R, Bruskewitz RC. Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. Urology 1994;44:876-82.
38. Perez CA, Pilepich MV, Garcia DM, Simpson JR, Zivnuska F, Hederman MA. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. NCI Monogr 1988;7:85-94.
39. Shipley WU, Prout GR, Coachman NM, McManus PL, Healey EA, Althausen AF, et al. Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1981). NCI Monogr 1988;7:67-73.
40. Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1990;143:538-44.
41. Leandri P, Rossignol G, Gautier J, Ramon J. Radical retropubic prostatectomy: morbidity and quality of life experience with 620 consecutive cases. J Urol 1992;147:883-7.
42. Quinlan DA, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991;145:998-1002.
43. Fowler FJ, Roman A, Barry MJ, Wasson J, Lu-Yao G, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy: the national medicare experience: 1988-1990 (Updated June 1993). Urology 1993;42:622-9.
44. Geary ES, Endinger TE, Stamey TA. Impotence, incontinence and vesical neck strictures following nerve-sparing radical prostatectomy. J Urol 1994;488A.
45. Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequalae of radical prostatectomy. Br J Urol 1994;74:352-8.